Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | PANK1 | Q8TE04 | 3/20 | 0.33 |
| ▸ | PANK3 | Q9H999 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964053 | 0.87 | PPARG (0.38) | BRAFKMT2AENPP2MTNR1AENPP3 | |
| SCHEMBL967854 | 0.84 | ENPP3 (0.35) | BRAFKMT2AENPP2MTNR1AENPP3 | |
| SCHEMBL961620 | 0.82 | BRAF (0.38) | BRAFMTNR1AENPP3ALDH1A1ENPP1 | |
| SCHEMBL961617 | 0.82 | BRAF (0.38) | BRAFMTNR1AENPP3ALDH1A1ENPP1 | |
| SCHEMBL966425 | 0.82 | MTNR1A (0.37) | BRAFKMT2AENPP2MTNR1AENPP3 | |
| SCHEMBL966561 | 0.80 | MTNR1A (0.37) | BRAFKMT2AENPP2MTNR1AENPP3 | |
| SCHEMBL5116348 | 0.79 | BRAF (0.37) | BRAFMTNR1AENPP3ENPP1 | |
| SCHEMBL5116334 | 0.79 | BRAF (0.37) | BRAFMTNR1AENPP3ENPP1 | |
| SCHEMBL966983 | 0.79 | MTNR1A (0.37) | BRAFKMT2AENPP2MTNR1AENPP3 | |
| SCHEMBL963933 | 0.79 | NPC1 (0.42) | KMT2AMTNR1APANK1PANK3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | BRAF 2412/4885KMT2A 1809/4885ENPP2 2566/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | BRAF 2850/4885KMT2A 2017/4885ENPP2 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.